Angiogenesis in non-small cell lung cancer.

Two processes are necessary for a tumor colony to grow and become invasive: angiogenesis and basement membrane degradation. Angiogenesis is the formation of new blood vessels from the endothelium of existing vasculature, in response to the metabolic demand of the tumor. Assessment of the degree of tumor angiogenesis may improve risk stratification in patients with lung cancer, especially those with early-stage disease. In addition, the strategy of blocking the mechanism of angiogenesis may prove to be an effective therapeutic alternative for patients with nonsmall cell lung cancer. Clinical trials evaluating novel antiangiogenic agents, including antibodies to vascular endothelial growth factor (VEGF) and compounds directed at the tyrosine kinase receptor, are ongoing.

[1]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[2]  S. Abe,et al.  Tumor angiogenesis of non–small cell lung cancer , 2003, Microscopy research and technique.

[3]  F. Khuri,et al.  Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Adjei,et al.  Novel targets for lung cancer therapy: part I. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. D’amico.  Molecular biologic substaging of non-small cell lung cancer. , 2002, The Journal of thoracic and cardiovascular surgery.

[6]  C. Reed,et al.  Tumor marker expression is predictive of survival in patients with esophageal cancer. , 2001, The Annals of thoracic surgery.

[7]  S. Hamilton-Dutoit,et al.  Patterns of angiogenesis in nonsmall‐cell lung carcinoma , 2001, Cancer.

[8]  R. Herbst,et al.  Angiogenesis and lung cancer: potential for therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  L. Liotta,et al.  Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  D. Harpole,et al.  Molecular biologic substaging of stage I lung cancer according to gender and histology. , 2000, The Annals of thoracic surgery.

[11]  K. O'Byrne,et al.  Angiogenesis and non-small cell lung cancer. , 2000, Lung cancer.

[12]  E. Brambilla,et al.  Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.

[13]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[14]  D. Harpole,et al.  A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. , 1999, The Journal of thoracic and cardiovascular surgery.

[15]  T. L. Moser,et al.  Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Luketich,et al.  The clinical significance of hepatocyte growth factor for non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[17]  K. Yasumoto,et al.  Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. , 1998, The Journal of thoracic and cardiovascular surgery.

[18]  R. Muraoka,et al.  Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[19]  J. Miller,et al.  Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. , 1998, The Journal of thoracic and cardiovascular surgery.

[20]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[21]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[23]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[24]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[25]  M. Iki,et al.  Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. , 1996, Cancer research.

[26]  W. Richards,et al.  Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. , 1996, The Annals of thoracic surgery.

[27]  A. Harris,et al.  Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis , 1995, The Journal of pathology.

[28]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[29]  A. Harris,et al.  Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer , 1995, The Journal of pathology.

[30]  S. Steinberg,et al.  Tumor angiogenesis in advanced stage ovarian carcinoma. , 1995, The American journal of pathology.

[31]  T. Saclarides,et al.  Tumor angiogenesis and rectal carcinoma , 1994, Diseases of the colon and rectum.

[32]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[33]  K. O'Byrne,et al.  Vascular endothelial growth factor expression in non-small cell lung cancer. , 2003, Methods in molecular medicine.

[34]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[35]  M. Volm,et al.  PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. , 1999, Anticancer research.

[36]  Harvey I. Pass,et al.  Lung cancer : principles and practice , 1996 .

[37]  M. Ranson,et al.  Chemotherapy in non-small cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  F. Hirsch,et al.  Staging and Prognosis , 1988 .